DALLAS, December 9, 2014 /PRNewswire/ --

RnRMarketResearch.com adds "Gaucher's Disease - Pipeline Review, H2 2014" market research report of 74 pages with an overview of the Gaucher's Disease's therapeutic pipeline to its online business intelligence library.

The Gaucher's Disease Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of this research includes a snapshot of the global therapeutic landscape of Gaucher's Disease, review of key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities as well as reviews of key players involved in the therapeutics development for Gaucher's Disease and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, provides a review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources as well as pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Gaucher's Disease pipeline on the basis of target, MoA, route of administration and molecule type along with latest news and deals relating related to pipeline products are provided in this research.

Companies involved in therapeutics development for Gaucher's Disease and discussed in this research include Amicus Therapeutics, Inc., Biosidus S.A., Dong-A Socio Group, ExSAR Corporation, Genzyme Corporation, greenovation Biotech GmbH, JCR Pharmaceuticals Co., Ltd, Lixte Biotechnology Holdings, Inc, Neuraltus Pharmaceuticals, Inc, Pharming Group N.V., Protalix BioTherapeutics, Inc. and UAB Profarma. Drug profiles are provided for afegostat tartrate + ERT, ambroxol, DOS-000011, eliglustat tartrate, Gluco-Cerebosidase, imiglucerase biosimilar, JR-101, LB-201, LB-205, NP-003, PRX-112, Recombinant Enzyme for Gaucher's Disease, Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease, Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases and Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease in this research available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=248286 .

2014 news and press releases related to Gaucher's Disease discussed in this research include:

Sep 02, 2014: Shire's VPRIV400 units/vial launched in Japan for the improvement of symptoms of Gaucher disease 65
Jul 04, 2014: Shire's VPRIV approved in Japan for the improvement of symptoms of Gaucher disease 65
Jun 18, 2014: Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease 66
Feb 14, 2014: Shire Announces FDA Approval of Manufacturing Facility for VPRIV (Velaglucerase Alfa for Injection) Drug Substance 67
Feb 12, 2014: Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy Gaucher's Disease - Pipeline Review, H2 2014 market research report: 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more pharmaceuticals market research reports on diseases and treatments at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research